A noticeable rise in the incidence of infectious diseases coupled with rise in the number of clinical trials is responsible for the growth of inactivated vaccines market.
An inactivated vaccine can be produced by growing the virus in culture media. This could be the initial limiting step, as the manufacturers need to know which conditions help in proliferation of viral growth.
The companies operating in inactivated vaccines market are devising means to reach out to the unexplored geographies of Latin America, Middle East & Africa, and Asia Pacific to draw more number of research institutes toward inactivated medicines.
They are looking forward toward shifting their production unit in these regions to lessen the overheads.
Inactivated vaccines comprise inactivated or dead bacteria and viruses, which are used on the regular basis as weakened versions of live viruses meant for stopping it from spreading the disease, but still encourage production of the T cells.
Inactivated vaccines are not influenced by the antibodies in host body as compared to live vaccines. This translates to their administration even on presence of antibodies in blood, such as after being given medication containing antibodies or during infancy.
Inactivated vaccines always need repeated doses for immunity to be obtained. The very first dose is the one preparing immune system to be responsive, whereas a protective immune response does not develop before the later or second doses.
However, inactivated vaccines have a curtailed capacity of producing a strong immune response for long-lasting immunity as compared to live attenuated vaccines. This factor may restrain the inactivated vaccines industry in the forecast period.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Increase in incidence of several bacterial and viral diseases at the global level has raised the demand for inactivated vaccines, which are, in turn, expected to bolster the inactivated vaccines market.
As per the report released by the WHO, influenza alone results in close to 3-5 million cases of extreme illness with close to 290,000 - 650,000 fatalities. It further states that around 222,000 typhoid-related fatalities happen every year globally.
The WHO also mentions that are 300-500 million cases of malaria, 33 million cases of HIV/AIDS, 333 million cases of sexually transmitted diseases (trichomonas, chlamydia, gonorrhea, and syphilis) worldwide.
Need to combat the infectious diseases mentioned above is thus catalyzing the inactivated vaccines market.
New inactivated vaccines are being introduced post-completion of the clinical studies, which is boosting the inactivated vaccines market revenue.
For instance, investigational inactivated varicella zoster virus vaccine (V212) from Merck specified that there was reduction in incidence of herpes zoster case by close to 64% in immunocompromised subjects in the very first phase 3 trial in 2017.
Clinical studies have further shown that V212 showed reduction by 83.7% in incidence pf post-herpetic neuralgia.
In April 2024, a novel oral vaccine for cholera received prequalification by the WHO. This inactivated oral vaccine Euvichol-S has efficacy similar to the existing vaccines but with a simplified formulation, thereby providing opportunities for increasing manufacturing capacity.
Continued clinical research activities as mentioned above are thus expanding inactivated vaccines market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest inactivated vaccines market insights, North America held the largest share in non-living vaccines landscape in 2023 and the scenario is expected to persist during the forecast period.
This is attributed to the support extended by the governments of the U.S. and Canada toward expansion of the healthcare sector including that of inactivated vaccines.
The U.S. Department of Health and Human Services shifting close to US$ 81 million in 2016 from the other projects toward development of vaccines for fighting Zika virus is one such example.
Asia Pacific’s inactivated vaccines market growth is ascribed to the key participants developing innovative products. An example of this activity is launching of JENVAC vaccine by Bharat Biotech for providing long-term protection as well as immunogenicity against the Japanese encephalitis. Though this vaccine came up in 2013, the research along the similar lines is on.
The key players in the inactivated vaccines market are launching new products in order to widen the customer base.
GSK plc, Novartis AG, Mylan N.V., Sanofi S.A., Boehringer Ingelheim International GmbH, Merck & Co., Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Bharat Biotech, Serum Institute of India, and INOVIO Pharmaceuticals, Inc. are some of the inactivated vaccines market manufacturers.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 40.6 Bn |
| Market Forecast (Value) in 2034 | US$ 74.8 Bn |
| Growth Rate (CAGR) | 5.7% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 40.6 Bn in 2023
It is projected to grow at a CAGR of 5.7% from 2024 to 2034
Growing prevalence of infectious diseases and increase in the number of clinical research activities
Viral vaccine segment accounted for the largest share in 2023
North America was the dominant region in 2023
GSK plc, Novartis AG, Mylan N.V., Sanofi S.A., Boehringer Ingelheim International GmbH, Merck & Co., Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Bharat Biotech, Serum Institute of India, and INOVIO Pharmaceuticals, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Inactivated Vaccines Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Inactivated Vaccines Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Inactivated Vaccines Market Analysis and Forecast, by Vaccine Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Vaccine Type, 2020-2034
6.3.1. Viral Vaccine
6.3.2. Bacterial Vaccine
6.4. Market Attractiveness, by Vaccine Type
7. Global Inactivated Vaccines Market Analysis and Forecast, by Method of Inactivation
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Method of Inactivation, 2020-2034
7.3.1. Solvent Detergent Method
7.3.2. Radiation Method
7.3.3. pH Concentration
7.3.4. Others (Heat Inactivation, etc.)
7.4. Market Attractiveness, by Method of Inactivation
8. Global Inactivated Vaccines Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Oral
8.3.2. Subcutaneous
8.3.3. Intravenous
8.4. Market Attractiveness, by Route of Administration
9. Global Inactivated Vaccines Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Homecare Settings
9.3.4. Others (Research Centers, etc.)
9.4. Market Attractiveness, by End-user
10. Global Inactivated Vaccines Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Inactivated Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Vaccine Type, 2020-2034
11.2.1. Viral Vaccine
11.2.2. Bacterial Vaccine
11.3. Market Attractiveness, by Vaccine Type
11.4. Market Value Forecast, by Method of Inactivation, 2020-2034
11.4.1. Solvent Detergent Method
11.4.2. Radiation Method
11.4.3. pH Concentration
11.4.4. Others (Heat Inactivation, etc.)
11.5. Market Attractiveness, by Method of Inactivation
11.6. Market Value Forecast, by Route of Administration, 2020-2034
11.6.1. Oral
11.6.2. Subcutaneous
11.6.3. Intravenous
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals
11.8.2. Specialty Clinics
11.8.3. Homecare Settings
11.8.4. Others (Research Centers, etc.)
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Vaccine Type
11.11.2. By Method of Inactivation
11.11.3. By Route of Administration
11.11.4. By End-user
11.11.5. By Country
12. Europe Inactivated Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Vaccine Type, 2020-2034
12.2.1. Viral Vaccine
12.2.2. Bacterial Vaccine
12.3. Market Attractiveness, by Vaccine Type
12.4. Market Value Forecast, by Method of Inactivation, 2020-2034
12.4.1. Solvent Detergent Method
12.4.2. Radiation Method
12.4.3. pH Concentration
12.4.4. Others (Heat Inactivation, etc.)
12.5. Market Attractiveness, by Method of Inactivation
12.6. Market Value Forecast, by Route of Administration, 2020-2034
12.6.1. Oral
12.6.2. Subcutaneous
12.6.3. Intravenous
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals
12.8.2. Specialty Clinics
12.8.3. Homecare Settings
12.8.4. Others (Research Centers, etc.)
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Vaccine Type
12.11.2. By Method of Inactivation
12.11.3. By Route of Administration
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Inactivated Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Vaccine Type, 2020-2034
13.2.1. Viral Vaccine
13.2.2. Bacterial Vaccine
13.3. Market Attractiveness, by Vaccine Type
13.4. Market Value Forecast, by Method of Inactivation, 2020-2034
13.4.1. Solvent Detergent Method
13.4.2. Radiation Method
13.4.3. pH Concentration
13.4.4. Others (Heat Inactivation, etc.)
13.5. Market Attractiveness, by Method of Inactivation
13.6. Market Value Forecast, by Route of Administration, 2020-2034
13.6.1. Oral
13.6.2. Subcutaneous
13.6.3. Intravenous
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospitals
13.8.2. Specialty Clinics
13.8.3. Homecare Settings
13.8.4. Others (Research Centers, etc.)
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Vaccine Type
13.11.2. By Method of Inactivation
13.11.3. By Route of Administration
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Inactivated Vaccines Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Vaccine Type, 2020-2034
14.2.1. Viral Vaccine
14.2.2. Bacterial Vaccine
14.3. Market Attractiveness, by Vaccine Type
14.4. Market Value Forecast, by Method of Inactivation, 2020-2034
14.4.1. Solvent Detergent Method
14.4.2. Radiation Method
14.4.3. pH Concentration
14.4.4. Others (Heat Inactivation, etc.)
14.5. Market Attractiveness, by Method of Inactivation
14.6. Market Value Forecast, by Route of Administration, 2020-2034
14.6.1. Oral
14.6.2. Subcutaneous
14.6.3. Intravenous
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals
14.8.2. Specialty Clinics
14.8.3. Homecare Settings
14.8.4. Others (Research Centers, etc.)
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Vaccine Type
14.11.2. By Method of Inactivation
14.11.3. By Route of Administration
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Inactivated Vaccines Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Vaccine Type, 2020-2034
15.2.1. Viral Vaccine
15.2.2. Bacterial Vaccine
15.3. Market Attractiveness, by Vaccine Type
15.4. Market Value Forecast, by Method of Inactivation, 2020-2034
15.4.1. Solvent Detergent Method
15.4.2. Radiation Method
15.4.3. pH Concentration
15.4.4. Others (Heat Inactivation, etc.)
15.5. Market Attractiveness, by Method of Inactivation
15.6. Market Value Forecast, by Route of Administration, 2020-2034
15.6.1. Oral
15.6.2. Subcutaneous
15.6.3. Intravenous
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals
15.8.2. Specialty Clinics
15.8.3. Homecare Settings
15.8.4. Others (Research Centers, etc.)
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Vaccine Type
15.11.2. By Method of Inactivation
15.11.3. By Route of Administration
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. GSK plc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Novartis AG
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Mylan N.V.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Sanofi S.A.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Boehringer Ingelheim International GmbH
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Merck & Co., Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. F. Hoffmann-La Roche AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Bristol-Myers Squibb Company
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Bharat Biotech
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Serum Institute of India
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. INOVIO Pharmaceuticals, Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
List of Tables
Table 01: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
Table 02: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
Table 03: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 04: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 05: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 06: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 07: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
Table 08: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
Table 09: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 10: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 11: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
Table 13: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
Table 14: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 15: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 16: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
Table 18: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
Table 19: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 20: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
Table 23: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
Table 24: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 25: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 26: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
Table 28: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
Table 29: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 30: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Inactivated Vaccines Market Size (US$ Bn), by Region, 2023 and 2034
Figure 02: Global Inactivated Vaccines Market Revenue (US$ Bn), by Vaccine Type, 2023
Figure 03: Global Inactivated Vaccines Market Value Share, by Vaccine Type, 2023
Figure 04: Global Inactivated Vaccines Market Revenue (US$ Bn), by Method of Inactivation, 2023
Figure 05: Global Inactivated Vaccines Market Value Share, by Method of Inactivation, 2023
Figure 06: Global Inactivated Vaccines Market Revenue (US$ Bn), by Route of Administration, 2023
Figure 07: Global Inactivated Vaccines Market Value Share, by Route of Administration, 2023
Figure 08: Global Inactivated Vaccines Market Revenue (US$ Bn), by End-user, 2023
Figure 09: Global Inactivated Vaccines Market Value Share, by End-user, 2023
Figure 10: Global Inactivated Vaccines Market Value Share, by Region, 2023
Figure 11: Global Inactivated Vaccines Market Value (US$ Bn) Forecast, 2020-2034
Figure 12: Global Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 13: Global Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 14: Global Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
Figure 15: Global Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
Figure 16: Global Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 17: Global Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 18: Global Inactivated Vaccines Market Revenue (US$ Bn), by End-user, 2023
Figure 19: Global Inactivated Vaccines Market Value Share, by End-user, 2023
Figure 20: Global Inactivated Vaccines Market Value Share Analysis, by Region, 2023 and 2034
Figure 21: Global Inactivated Vaccines Market Attractiveness Analysis, by Region, 2024-2034
Figure 22: North America Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 23: North America Inactivated Vaccines Market Attractiveness Analysis, by Country, 2024-2034
Figure 24: North America Inactivated Vaccines Market Value Share Analysis, by Country, 2023 and 2034
Figure 25: North America Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 26: North America Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
Figure 27: North America Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 28: North America Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
Figure 29: North America Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 30: North America Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
Figure 31: North America Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 32: North America Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
Figure 33: Europe Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 34: Europe Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 35: Europe Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 36: Europe Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 37: Europe Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
Figure 38: Europe Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 39: Europe Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
Figure 40: Europe Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 41: Europe Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
Figure 42: Europe Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 43: Europe Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
Figure 44: Asia Pacific Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 45: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 46: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 47: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 48: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
Figure 49: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 50: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 52: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
Figure 53: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 54: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2023-2034
Figure 55: Latin America Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 56: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 57: Latin America Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 58: Latin America Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 59: Latin America Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
Figure 60: Latin America Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 61: Latin America Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
Figure 62: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 63: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
Figure 64: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 65: Latin America Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
Figure 66: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 67: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 68: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 69: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 70: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
Figure 71: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 72: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
Figure 73: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 74: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
Figure 75: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 76: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Inactivated Vaccines Market
